ライフサイエンスコーパス: vision loss

1 l or missing types are responsible for color vision loss.

2 screening is indicated to avoid irreversible vision loss.

3 B are linked to photoreceptor impairment and vision loss.

4 NIU requires long-term treatment to prevent vision loss.

5 re retinal toxicity, including 1 with severe vision loss.

6 rget in the mechanism of complex 1-deficient vision loss.

7 Prevalence and main causes of vision loss.

8 e past year (OR, 1.61) were risk factors for vision loss.

9 an lead to iatrogenic glaucoma and permanent vision loss.

10 l break formation and to prevent the central vision loss.

11 ntral to the pathogenesis of major causes of vision loss.

12 asing numbers is needed to address avoidable vision loss.

13 t undesirable effects including, ironically, vision loss.

14 cular dystrophies (MDs) are a major cause of vision loss.

15 r disease or trauma that result in permanent vision loss.

16 acts to relatively inexpensive prevention of vision loss.

17 omplex retinal disease that leads to central vision loss.

18 tinal degenerations that lead to progressive vision loss.

19 that encodes for nephrocystin-5 (NPHP5), had vision loss.

20 sionally the cornea is infected resulting in vision loss.

21 is an attractive treatment option to prevent vision loss.

22 2 Humphrey visual fields, or the duration of vision loss.

23 orm of advanced AMD and leads to significant vision loss.

24 ation (AMD) is a major cause of irreversible vision loss.

25 ng causes of retinal disease and age-related vision loss.

26 CS shows potential to help prevent avoidable vision loss.

27 enic edema and neural tissue damage, causing vision loss.

28 on, prevented cell death, and protected from vision loss.

29 tural changes precede clinically significant vision loss.

30 o analyze potential predictors for permanent vision loss.

31 the influence of baseline patient factors on vision loss.

32 mended comprehensive eye care for preventing vision loss.

33 tion tended to be particularly vulnerable to vision loss.

34 vastating ocular condition causing permanent vision loss.

35 on; only half were aware of smoking risks on vision loss.

36 ients (22%) and 6 eyes (13%) had significant vision loss.

37 of neural plasticity in the context of adult vision loss.

38 retinopathy is a major cause of irreversible vision loss.

39 lion cells (RGCs), resulting in irreversible vision loss.

40 untreatable and leads to partial or complete vision loss.

41 ceptor degeneration resulting in progressive vision loss.

42 se the death of retinal neurons and profound vision loss.

43 glaucoma patients with different degrees of vision loss.

44 ompromises corneal transparency resulting in vision loss.

45 acula and/or peripapillary region leading to vision loss.

46 ammatory condition associated with permanent vision loss.

47 analyses) were used to estimate freedom from vision loss.

48 cess as their renal disease, and neither had vision loss.

49 urological deficits, hearing impairment, and vision loss.

50 between ffERG abnormalities and the rate of vision loss.

51 nked to time since diagnosis and location of vision loss.

52 ergetics, and mutations in complex I lead to vision loss.

53 in diameter were deemed high risk (hrTS) for vision loss.

54 ons and photoreceptors is a leading cause of vision loss.

55 een medication nonadherence and glaucomatous vision loss.

56 as chronic obstructive pulmonary disease and vision loss.

57 c macular edema (ci-DME) is a major cause of vision loss.

58 around the optic nerve or macula with severe vision loss.

59 esence of ORHR was not associated with rapid vision loss.

60 eading IVI scores, respectively) to quantify vision loss.

61 n who need intervention to prevent permanent vision loss.

62 photoreceptor degeneration leads to central vision loss.

63 reat patients efficiently to avoid potential vision loss.

64 sfunction is an important cause of heritable vision loss.

65 nd painful disease that is a common cause of vision loss.

66 ccess in generating treatments that can halt vision loss.

67 associated complications that can result in vision loss.

68 cell death are major causes of irreversible vision loss.

69 posure symptoms (8 malignancies), unilateral vision loss (3 malignancies), and facial nerve paresis (

70 retinopathy (13.1%), referral (9.7%), sudden vision loss (9.3%), and trauma (8.0%) were the commonest

71 sual sensory processing, introducing central vision loss (a scotoma).

72 Individuals with vision loss adapt their locomotion and gaze behaviour to

73 eyes with diabetic macular edema (DME) with vision loss after macular laser photocoagulation is clin

74 eyes with diabetic macular edema (DME) with vision loss after macular laser photocoagulation is clin

75 ic outcomes in eyes experiencing substantial vision loss after macular laser photocoagulation treatme

76 ic outcomes in eyes experiencing substantial vision loss after macular laser photocoagulation treatme

77 g on an endoscope lens capable of preventing vision loss after repeated submersions in blood and mucu

78 ting myopia-related ocular complications and vision loss among almost 1 billion people with high myop

79 esions were smaller and associated with less vision loss among eyes in the FH group.

80 Perception of vision loss among patients with glaucoma may be associat

81 D) is the most common cause of uncorrectable vision loss among the elderly in developed countries.

82 acular edema is one of the leading causes of vision loss among working-age adults in the United State

83 should be considered in patients with acute vision loss and abnormalities on NIR-REF imaging, especi

84 cient model that leads to RGC loss and rapid vision loss and allows for streamlined testing of potent

85 A man developed vision loss and bilateral subhyaloid, outer plexiform, a

86 ay a significant role in preventing glaucoma vision loss and blindness in people of African descent l

87 f normal tension glaucoma, a common cause of vision loss and blindness that occurs without grossly ab

88 of individuals from experiencing unnecessary vision loss and blindness, decrease associated costs to

89 ints are needed that reliably predict future vision loss and can be easily measured.

90 treated, it may result in varying degrees of vision loss and even blindness.

91 ibed OCT finding associated with significant vision loss and is an essential element of a novel OCT-b

92 ung child with bilateral rapidly progressive vision loss and macular disturbance, blood film microsco

93 A 36-year-old woman presented with vision loss and metamorphopsia in her right eye while 21

94 ucidate further the relative contribution of vision loss and neurofibromatosis type 1 co-diagnosis wi

95 l of CMT2A that developed severe early onset vision loss and neurological deficits, axonal degenerati

96 While ELOVL4 mutations are linked to vision loss and neuronal dysfunctions, the roles of VLC-

97 nting characteristics and incidence rates of vision loss and ocular complications in a cohort of poly

98 Noninfectious uveitis results in vision loss and ocular complications without adequate tr

99 outcome measures included incidence rates of vision loss and retinal detachment (RD).

100 eceived anti-VEGF therapy to prevent further vision loss and retinal neovascularization due to extens

101 The relationship between functional vision loss and structural changes of the optic nerve he

102 in diameter were deemed low risk (lrTS) for vision loss and those larger than 2 mm in diameter were

103 e performed to calculate cumulative rates of vision loss and to assess risk factors for vision loss,

104 VL was associated with greater acceptance of vision loss and use of instrumental coping, good social

105 RD confers the greatest risk of incident vision loss, and once 25% or more of the retina is invol

106 These diseases cause irreversible vision loss, and provide a significant health and econom

107 Low IOP after trabeculectomy, reoperation, vision loss, and surgical failure.

108 mes that were examined included reoperation, vision loss, and surgical failure.

109 mblyopia results in permanent, uncorrectable vision loss, and the benefits of screening and treatment

110 hemes coded and categorized as the impact of vision loss, and understandings of the disease and its m

111 insights into the molecular pathogenesis of vision loss associated with an RPE65 point mutation.

112 and offer a new rationale and mechanism for vision loss associated with genetic defects in Tulp1.

113 Aflibercept seems to limit vision loss associated with radiation maculopathy.

114 is required to validate the implied risk of vision loss associated with these terms.

115 are required to quantify the implied risk of vision loss associated with these terms.

116 No baseline metric was associated with vision loss at 1 year.

117 uity, there was no significant difference in vision loss at 2 years whether eyes were initially manag

118 93; P < 0.001) with 46% of eyes experiencing vision loss at 5 years (with or without progression to l

119 beta-2 microglobulin and Cx3cr1, and during vision loss at P31 (B2m, Tlr 2, 3, 4, C1qa, Cx3cr1 and F

120 gnitive delay, cerebral palsy, or hearing or vision loss) at 22 to 26 months of age, corrected for pr

121 l basis could reduce drastically the rate of vision loss attributed to DR.

122 VA in patient-reported outcome evaluation of vision loss because it may better reflect its impact on

123 n demonstrate proliferative retinopathy with vision loss, but lack of consensus exists regarding scre

124 in the eye and the brain before substantial vision loss can be detected clinically using current tes

125 The pattern of vision loss can be highly asymmetric, such that an intac

126 The majority of AMD-associated severe vision loss cases are due to exudative AMD, characterize

127 apy progress has raised the possibility that vision loss caused by inherited retinal degeneration can

128 In addition to vision loss caused by macular edema and pathological ang

129 ner plexiform layers, can be correlated with vision loss caused by optic nerve disease.

130 This vision loss causes difficulty identifying obstacles and

131 eatment for glaucoma, one of the most common vision loss conditions worldwide.

132 degeneration (AMD), a leading contributor of vision loss, currently lacks comprehensive treatment.

133 data sources permitted modelling of cause of vision loss data from 1990 to 2015, further disaggregati

134 rovement as well as reduction of the risk of vision loss due to Age-Related Macular Degeneration (AMD

135 examinations to identify patients at risk of vision loss due to aSAH.

136 Preventable vision loss due to cataract (reversible with surgery) an

137 rited macular dystrophy, is characterized by vision loss due to central retinal atrophy.

138 requiring intervention (P = 0.049) and less vision loss due to glaucoma progression (P = 0.046).

139 ghted controls and participants with central vision loss due to macular degeneration (MD).

140 treatment would aid in reducing the rate of vision loss, enabling timely and accurate diagnoses.

141 as are neurodegenerative diseases that cause vision loss, especially in the elderly.

142 K-related endophthalmitis may lead to severe vision loss, even with prompt and appropriate treatment.

143 Vision loss following episcleral brachytherapy for uveal

144 ine risk calculator was developed to predict vision loss following episcleral brachytherapy.

145 Causes of vision loss for children with vision impairment (recorde

146 Comparing vision loss from baseline by culture result, at final fo

147 sed to screen for moderate to severe central vision loss from glaucoma.

148 duction prevents development of glaucoma and vision loss from glaucoma.

149 Children experiencing vision loss from their optic pathway gliomas frequently

150 r of people affected by the common causes of vision loss has increased substantially as the populatio

151 oroidal neovascular stage before substantial vision loss has occurred and to consider dietary supplem

152 ntify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual

153 s a severe retinal disorder that can lead to vision loss, however, its underlying mechanism has not b

154 Many ocular syphilis patients experienced vision loss; however, most improved posttreatment.

155 fibroblasts offers an opportunity to reverse vision loss; however, the generation of sensory neuronal

156 ulitis was associated with a reduced risk of vision loss (HR 0.36, 95% CI 0.15-0.82, P = .01).

157 hazard ratio [HR], 0.73; 95% CI, 0.32-1.68), vision loss (HR, 1.77; 95% CI, 0.81-3.88) or surgical fa

158 axon regeneration after injury, and reverses vision loss in a mouse model of glaucoma and in aged mic

159 To prevent irreversible vision loss in age-related macular degeneration (AMD), i

160 genic process that critically contributes to vision loss in age-related macular degeneration, is uncl

161 The overall prevalence of vision loss in Australia was 6.6% (95% confidence interv

162 Macular edema is the leading cause of vision loss in bilateral chronic noninfectious posterior

163 A 28-year-old woman presented with gradual vision loss in both eyes and nyctalopia for 2 years.

164 his study aimed at identifying the causes of vision loss in children attending the national referral

165 The vision loss in CLN5 deficient mice is primarily caused b

166 is the primary cause of blindness and severe vision loss in developed countries and is responsible fo

167 (AMD)-the main cause of irreversible severe vision loss in developed countries-given the suggestion

168 ular edema (DME) is the most common cause of vision loss in diabetic patients.

169 pathological and clinical stages leading to vision loss in diabetic retinopathy (DR) are highlighted

170 or neovascular eye disease, a major cause of vision loss in diabetic retinopathy and age-related macu

171 ly contributing to retinal complications and vision loss in diabetic retinopathy.

172 ic macular edema (DME) is a leading cause of vision loss in diabetics.

173 the blood-retinal barrier (BRB) is linked to vision loss in DR and AMD.

174 As one of the leading causes of central vision loss in elderly population, worldwide cases of ag

175 rehabilitative services to address childhood vision loss in Eritrea.

176 This study explored the causes of vision loss in Eritrean children using hospital based da

177 ributes to macular edema, a leading cause of vision loss in eye pathologies such as diabetic retinopa

178 ptor degeneration is a cause of irreversible vision loss in incurable blinding retinal diseases inclu

179 nwide survey on the prevalence and causes of vision loss in Indigenous and non-Indigenous Australians

180 the normally avascular photoreceptors cause vision loss in many eye diseases, such as age-related ma

181 Photoreceptor death is the root cause of vision loss in many retinal disorders, and there is an u

182 receptor cell death is the ultimate cause of vision loss in many retinal disorders, and there is an u

183 and macular degeneration cause irreversible vision loss in more than 10 million people worldwide.

184 ould be a risk factor for retinal damage and vision loss in nondiabetic as well as diabetic patients.

185 ascularization (CNV) is a prevalent cause of vision loss in patients with age-related macular degener

186 s a common complication and a major cause of vision loss in patients with diabetes mellitus.

187 for diabetic retinopathy (DR) is to prevent vision loss in patients with diabetes mellitus.

188 ic macular edema (DME) is a leading cause of vision loss in patients with diabetes.

189 ible pharmacological approach that can delay vision loss in patients with RPE65 mutations.

190 herapeutic intervention that delays daylight vision loss in patients with RPE65 mutations.

191 tion that manifests in acute and progressive vision loss in patients.

192 tic retinopathy (DR) is important to prevent vision loss in persons with diabetes.

193 developing brain that can lead to permanent vision loss in the affected eye.

194 hronic eye condition that leads to permanent vision loss in the central visual field.

195 ar degeneration (AMD) - the leading cause of vision loss in the elderly - share many risks factors as

196 on (AMD), the most common cause of incurable vision loss in the elderly worldwide.

197 ceptor survival, and is the leading cause of vision loss in the elderly.

198 ite populations, AMD is a prominent cause of vision loss in the nonindigenous Australian population.

199 A 41-year-old woman presented with painless vision loss in the right eye for 1 week.

200 ld female patient presented with progressive vision loss in the right eye.

201 Amblyopia was the most common cause of vision loss in the visually immature versus cataract in

202 macular issues were the most common cause of vision loss in this cohort.

203 Macular ischemia increased the risk of vision loss in vasculitis eyes by 4.4 times.

204 ) is a leading cause of irreversible, severe vision loss in Western countries.

205 ovascularization (CNV) is the major cause of vision loss in wet age-related macular degeneration (AMD

206 inopathy, the leading cause of blindness and vision loss in working age adults.

207 acular edema (DME), the most common cause of vision loss in working-age Americans, do not respond ade

208 displayed progressive gait abnormalities and vision loss, in addition to biochemical defects consiste

209 arkably, an AMD-like phenotype consisting of vision loss, increased retinal pigmented epithelium (RPE

210 Vision loss is among the first clinical signs in childho

211 r in diseases such as glaucoma, irreversible vision loss is due to the death of retinal ganglion cell

212 f visual cortex plasticity following central vision loss is essential both for clarifying the mechani

213 Proper information on causes of childhood vision loss is essential in developing appropriate strat

214 Despite slow disease progression in humans, vision loss is inevitable; therefore, development of vis

215 Vision loss is more prevalent in Indigenous Australians

216 ly good, but the true incidence of permanent vision loss is probably still underestimated.

217 Severe vision loss is rare in MacTel and is related to photorec

218 s adapt eye movements in response to central vision loss is still not well understood and carries imp

219 c retinopathy (DR), the most common cause of vision loss, is caused by damage to the small blood vess

220 No patient developed severe vision loss (</=15 letters) and vision was stable or imp

221 neration was attributed as the main cause of vision loss (<6/12 in the better eye) in 23 of 208 nonin

222 inopathy was attributed as the main cause of vision loss (<6/12 in the better eye) in 9% and 19% of n

223 itis is associated with an increased risk of vision loss, mainly secondary to macular ischemia, and h

224 These results suggest that central vision loss may give rise to cortical thinning, while in

225 ndilated examination, delayed-onset painless vision loss, mild anterior chamber and vitreous inflamma

226 Patients with no vision loss (NVL), partial vision loss (PVL), and severe

227 -related serious adverse events resulting in vision loss occurred in either group.

228 ompt versus deferred laser groups, there was vision loss of >/=10 letters in 9% versus 8%, an improve

229 Vision loss of 15 or more letters was evaluated as a new

230 reatment Diabetic Retinopathy Study letters, vision loss of more than 5 Early Treatment Diabetic Reti

231 photoreceptor dysfunction triggering central vision loss of these patients, we model the stimulation

232 ive gait kinematics in subjects with central vision loss, older controls, and younger controls.

233 Therefore we examined the impact of central vision loss on motion perception using random dot kinema

234 , we explore the possible effects of central vision loss on the optimal saccades during a face identi

235 dinal population-based data on the effect of vision loss on vision-specific functioning (VSF) are sca

236 ular VA seems to underestimate the impact of vision loss on VRQoL indices compared with binocular VA.

237 ular pressure (IOP) readings of <6 mmHg with vision loss or >17 mmHg without glaucoma medications (co

238 Glaucoma is a common cause of vision loss or blindness and reduction of intraocular pr

239 F by reverse transcriptase PCR, or (iii) new vision loss or hearing loss.

240 chondrial bioenergetics may lead to isolated vision loss or life-threatening systemic disease, depend

241 Serious complications producing vision loss or requiring reoperation occurred with simil

242 2 consecutive visits after 3 months, severe vision loss, or de novo glaucoma surgery.

243 Participants presented with rapid bilateral vision loss over 1 to 18 months, with mean VA deteriorat

244 1 year of progressive, bilateral, peripheral vision loss, photopsias, and nyctalopia.

245 Given the risk of added vision loss posed by exudative vitreoretinopathy in pati

246 Glaucoma is a leading cause of irreversible vision loss predicted to affect more than 100 million pe

247 Patients with no vision loss (NVL), partial vision loss (PVL), and severe vision loss (SVL) were mat

248 asked about various possible consequences of vision loss, quality of life ranked as the top concern f

249 reafter laser control) eyes with substantial vision loss receiving treatment with intravitreal aflibe

250 reafter laser control) eyes with substantial vision loss receiving treatment with intravitreal aflibe

251 he high rates of progression to late AMD and vision loss (regardless of progression to late AMD).

252 diabetic retinopathy are prevalent causes of vision loss requiring frequent intravitreous injections

253 f vision loss and to assess risk factors for vision loss, respectively.

254 Retinal screening examinations can prevent vision loss resulting from diabetes but are costly and h

255 s are required to delay or prevent avoidable vision loss resulting from DR in Indigenous Australian c

256 fter surgery, all eyes demonstrated painless vision loss resulting from HORV.

257 Patients with vision loss resulting from ME secondary to a branch or (

258 s of the listener's sightedness, duration of vision loss, sex, or age.

259 l model to predict where humans with central vision loss should direct their eye movements in face id

260 to the development of subretinal lesions and vision loss.SIGNIFICANCE STATEMENT The photoreceptors ar

261 rations emerging after central or peripheral vision loss suggest that cerebral reorganization occurs

262 (NVL), partial vision loss (PVL), and severe vision loss (SVL) were matched 1:1:1 based on age, race,

263 onclusion, CLN5 deficient mice develop early vision loss that reflects the condition reported in clin

264 etinopathy-related macular edema and prevent vision loss through 48 weeks of therapy.

265 rough the foveal center leads to significant vision loss through the availability of natural history

266 The disease causes vision loss through the degeneration of retinal ganglion

267 Cataracts cause vision loss through the large-scale aggregation of eye l

268 CI, 1.20-2.85; P = .005) were predictive of vision loss to a VA of less than 20/200.

269 th presented narrows down the cause of acute vision loss to the cone photoreceptor outer segment and

270 Vision loss (to visual acuity [VA] worse than 20/50 and

271 During follow-up 226 eyes (66%) experienced vision loss up to 20/50, but most recovered.

272 ence and main causes of bilateral presenting vision loss (visual acuity <6/12 in the better eye) were

273 The prevalence of vision loss was 11.2% (95% CI, 9.5-13.1) in Indigenous A

274 Vision loss was 2.8 times more prevalent in Indigenous A

275 This vision loss was associated with shorter time to presenta

276 As majority of the causes of vision loss was due to avoidable causes, we recommended

277 congenital anomaly, neoplasm, and hearing or vision loss was evaluated from birth to age 4 years.

278 A dramatic peak in age at onset of vision loss was found among males between 14 and 26 year

279 The main reasons for postimplantation vision loss was glaucoma (12/31, 39%), and the risk of g

280 ision and photoreceptors but the rate of rod vision loss was greater than the rate of photoreceptor d

281 Complete vision loss was noted in 27% of the eyes with ACI that w

282 Over two-thirds (69.9%) of vision loss was potentially avoidable in nature.

283 The risk of vision loss was significantly more in the retinal vascul

284 Vision loss was uncommon but occurred with similar frequ

285 y and the pathologic mechanisms that lead to vision loss, we generated mouse models lacking IMPG1/IMP

286 The leading causes of vision loss were cataract (19.7%), corneal scars (15.7%)

287 gy, significant cataract, or nonglaucomatous vision loss were excluded.

288 s those who progressed to moderate or severe vision loss were older than 30 years.

289 Contrast sensitivity and color vision loss were quantified.

290 ndigenous Australians, the leading causes of vision loss were uncorrected refractive error (60.8%), c

291 ndigenous Australians, the leading causes of vision loss were uncorrected refractive error (61.3%), c

292 The leading causes of vision loss were uncorrected refractive error and catara

293 it maculopathy (OPM) is an uncommon cause of vision loss with no standard surgical treatment.

294 ts with nAMD, particularly given the risk of vision loss with undertreatment observed in the real wor

295 Myopia is a common cause of vision loss, with uncorrected myopia the leading cause o

296 d macular degeneration is a leading cause of vision loss worldwide, and VEGF inhibitors are the prima

297 ation (AMD), a leading cause of irreversible vision loss worldwide, are variants associated with CFH-

298 ma (POAG) is a leading cause of irreversible vision loss worldwide, with elevated intraocular pressur

299 cular edema (DME) remains a leading cause of vision loss worldwide.

300 ction via retinal screening can prevent most vision loss, yet screening rates are consistently lower